DRKS00000021招募中3 期
Olanzapine augmentation therapy in treatment-resistent depression: a double-blind placebo-controlled trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
入选标准
- •major depression without psychotic features (DSM-IV definition)
- •- therapy resistance (two courses of antidepressant from different classes > 3 weeks in adequate dose), HAM-D more or equal 17
- •- age: 18-65
排除标准
- •- bipolar disorder
- •- active alcohol or illicit drug use
- •- female without effective contraception
- •- severe medical conditions, epilepsy
- •- psychotic features ( P1, P3 an P6 more or equal 2 at inclusion)
研究者
相似试验
尚未招募
3 期
Olanzapine in pediatric chemotherapy induced nausea and vomiting iIRCT20120415009475N14Vice Chancellor for research of Shahid Beheshti University of Medical Sciences56
已完成
3 期
A clinical trial to study the effect of olanzapine in patients receiving highly emetogenic chemotherapyCTRI/2019/01/017317All India Institute of Medical Sciences128
进行中（未招募）
不适用
Optimal Duration of Olazapine Add-on therapy in Major Depression: A double-blind, placebo-controlled, randomized, Phase III, Pilot Study in parallel group Design - OLA-DMajor DepressionEUCTR2007-000512-82-DECharité Universitätsmedizin Berlin
已完成
2 期
The efficacy of combination of Olanzapine, Aprepitant, Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving autologous peripheral blood stem cell transplantation for multiple myelomamultiple myelomaJPRN-UMIN000035970Hitachi general hospital52
已完成
3 期
Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapyChemotherapy-induced Nausea and VomitingNCT04075955CR-CSSS Champlain-Charles-Le Moyne30